What to know about new diagnostic tools, targeted medications, and other recent advances in the treatment of metastatic NSCLC ...

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus FLOT yields better outcomes than FLOT alone.

For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, ...

Proteomics International (ASX:PIQ) has popped as much as +6% today after reporting the “high accuracy” of its blood test for ...

The phase 3 MATTERHORN study “supports the global adoption of perioperative durvalumab plus FLOT for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Janjigian of ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Paclitaxel is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and locally ...

In a systematic review and meta-analysis of 7 population-based studies comprising 34,454 patients with Barrett esophagus, investigators estimated esophageal adenocarcinoma (EAC)-related and ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved ...

EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...